Tamoxifen inhibits GH3 cell growth in culture via enhancement of apoptosis

Neurosurgery

Volumn 43, Issue 1, 1998, Pages 116-123

  Lee, So Young ^a   Ahn, Byung Tae ^b   Baik, Sang Ho ^a   Lee, Byung Lan ^a  

^a Seoul National University   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Apoptosis; Cell growth; GH3 cells; Prolactin; Tamoxifen

Indexed keywords

ALCOHOL; ANTIESTROGEN; BROMOCRIPTINE; BROXURIDINE; ESTRADIOL; PROLACTIN; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; GROWTH INHIBITION; HYPOPHYSIS TUMOR; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR CELL LINE; ANIMAL; CELL COUNT; CELL DIVISION; DRUG EFFECT; ELECTRON MICROSCOPY; HUMAN; METABOLISM; RADIATION INJURY;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BROMOCRIPTINE; CELL COUNT; CELL DIVISION; DOPAMINE AGONISTS; ESTRADIOL; HUMANS; MICROSCOPY, ELECTRON; NEOPLASMS, RADIATION-INDUCED; PITUITARY NEOPLASMS; PROLACTIN; RATS; RECEPTORS, DOPAMINE; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0032109874     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199807000-00076     Document Type: Article

References (44)

1. Albaro V, Touraine PH, Vozari KR, Bai-Grenier F, Birman P, Joubert D: Protein kinase C activity and expression in normal and adenomatous human pituitaries. Int J Cancer 50:724-730, 1992.
2. 3 cell growth. Endocrinology 112:1141-1143, 1983.
3. Bansal S, Lee LA, Woolf PD: Abnormal prolactin responsivity to dopaminergic suppression in hyperprolactinemic patients. Am J Med 71:961-966, 1981.
4. Bardon S, Vignon F, Montcourrier P, Rochefort H: Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 47:1441-1448, 1987.
5. Berthois Y, Katzenellenborgen JA, Katzenellenborgen BS: Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A 83:2496-2500, 1986.
6. Brue T, Pellegrini I, Priou A, Morange I, Jaquet P: Prolactinomas and resistance to dopamine agonists. Horm Res 38:84-89, 1992.
7. Caronti B, Palladini G, Bevilacqua MG, Petrangeli E, Fraioli B, Cantore G, Tamburrano G, Carapella CM, Jaffrain-Rea ML: Effects of 17 beta-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas: Correlation with specific cellular receptors. Tumour Biol 14:59-68, 1993.
8. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MH, Law RE: Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345:43-46, 1994.
9. Couldwell WT, Law RE, Hinton DR, Gopalakrishna R, Yong VW, Weiss MH: Protein kinase C and growth regulation of pituitary adenomas. Acta Neurochir Suppl (Wien) 65:22-26, 1996.
10. 3 cells: A prolactin-secreting clone resistant to the inhibitory action of dopamine. Endocrinology 106:718-723, 1980.
11. Crosignani PG, Ferrari C, Malinverni A: Effect of central nervous system dopaminergic activation on prolactin secretion in man: Evidence for a common central defect in hyperprolactinemic patients with and without radiological signs of pituitary tumors. J Clin Endocrinol Metab 51:1068-1073, 1980.
12. De Carvalho-Brunet N, Picart R, Tixier-Vidal A: 17 beta-estradiol regulates prolactin secretion but not cell proliferation of GH3B6 cells in chemically defined medium. Mol Cell Endocrinol 39:49-60, 1985.
13. De Quijada M, Timmermans HAT, Lamberts SWJ: Tamoxifen suppresses both the growth of prolactin-secreting pituitary tumors and normal prolactin synthesis in the rat. J Endocrinol 86:109-116, 1980.
14. De Quijada M, Timmermans HAT, Lamberts SWJ, MacLeod RM: Tamoxifen enhances the sensitivity of dispersed prolactin-secreting pituitary tumor cells to dopamine and bromocriptine. Endocrinology 106:702-706, 1980.
15. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK: bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study. J Clin Oncol 15:1916-1922, 1997.
16. 3 cells to the dopaminergic inhibition of prolactin. Endocrinology 107:1022-1026, 1980.
17. Fine SA, Frohman LA: Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors. J Clin Invest 61:973-980, 1978.
18. Hamada M, Naomoto Y, Fujiwara T, Kamikawa Y, Tanaka N: Suppressed apoptotic induction in esophageal squamous cell carcinomas expressing extensive p53 protein. Jpn J Clin Oncol 26: 398-404, 1996.
19. Hasegawa M, Mitsuhashi N, Yamakawa M, Furuta M, Maebayashi K, Imai R, Hayakawa K, Niibe H: p53 protein expression and radiation-induced apoptosis in human tumors transplanted to nude mice. Radiat Med 15:171-176, 1997.
20. Ishizuka T, Ito Y, Murayama M, Miura K, Nagao S, Nozawa Y: Hormone-induced redistribution of protein kinase C in human pituitary adenomas. Clin Chim Acta 170:351-354, 1987.
21. Ito A, Kawashima K, Fujimoto N, Watanabe H, Naito M: Inhibition by 2-bromo-alpha-ergocriptine and tamoxifen of the growth of an estrogen-dependent transplantable pituitary tumor (MtT/F84) in F344 rats. Cancer Res 45:6436-6441, 1985.
22. Iwadate Y, Fujimoto S, Tagawa M, Namba H, Sueyoshi K, Hirose M, Sakiyama S: Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 69: 236-240, 1996.
23. Kim WH, Schnaper HW, Nomizu M, Yamada Y, Kleinman HK: Apoptosis in human fibrosarcoma cells is induced by a multimeric synthetic Tyr-Ile-Gly-Ser-Arg (YIGSR)-containing polypeptide from laminin. Cancer Res 54:5005-5010, 1994.
24. Lamberts SWJ, MacLeod RM: The inability of bromocriptine to inhibit prolactin secretion by transplantable rat pituitary tumors: Observations on the mechanism and dynamics of the autofeedback regulation of prolactin secretion. Endocrinology 104:65-70, 1979.
25. Lamberts SWJ, Verleun T: Differences in the mechanism of the inhibitory actions of catecholestrogens, tamoxifen and high concentrations of estrogens on prolactin release by cultured rat pituitary tumor cells. Eur J Cancer Clin Oncol 23:1117-1123, 1987.
26. Lamberts SWJ, Verleun T, Hofland L, Oosterom R: Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab 63:1342-1347, 1986.
27. Lee BL, Lee DL, Lee HY, Lee DS, Baik SH: Direct effects of estrogen on mammotrope proliferation in primary cultures of male rat anterior pituitary cells. Seoul J Med 36:113-120, 1995.
28. Lee BL, Unabia G, Childs G: Expression of follistatin mRNA by somatotropes and mammotropes early in the rat estrous cycle. J Histochem Cytochem 41:955-960, 1993.
29. Lieberman ME, Jordan VC, Fritsch M, Santos MA, Gorski J: Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. J Biol Chem 258:4734-4740, 1983.
30. Lloyd RV, Jin L, Field K, Kulig E: Effects of estrogens on pituitary cell and pituitary tumor growth. Pathol Res Pract 187:584-586, 1991.
31. Malaab SA, Pollak MN, Goodyer CG: Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur J Cancer 28A:788-793, 1992.
32. Nagy I, Valdenegro CA, MacLeod RM: Effect of antiestrogens on pituitary prolactin production in normal and pituitary tumor-bearing rats. Neuroendocrinology 30:389-395, 1980.
33. Naor Z: Further characterization of protein kinase-C subspecies in the hypothalamo-pituitary axis: Differential activation by phorbol esters. Endocrinology 126:1521-1526, 1990.
34. O'Brian CA, Liskamp RM, Soloman DH, Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer Res 45:2462-2465, 1985.
35. Prysor-Jones RA, Silverlight JJ, Jenkins JS: Effects of tamoxifen on growth and prolactin secretion of rat pituitary tumors. J Endocrinol 97:261-266, 1983.
36. Saito Y, Milross CG, Hittelman WN, Li D, Jibu T, Peters LJ, Milas L: Effect of radiation and paclitaxel on p53 expression in murine rumors sensitive or resistant to apoptosis induction. Int J Radiat Biol Phys 38:623-631, 1997.
37. Shull JD, Beams FE, Baldwin TM, Gilchrist CA, Hrbek MJ: The estrogenic and antiestrogenic properties of tamoxifen in GH4C1 pituitary tumor cells are gene specific. Mol Endocrinol 6:529-535, 1992.
38. Tashjian AH, Bancroft FC, Levin L: Production of both prolactin and growth hormone by clonal strains of rat pituitary tumor cells. J Cell Biol 47:61-70, 1970.
39. 3 rat pituitary tumor cells by monohydroxytamoxifen is associated with changes in the properties of the estrogen receptor. J Steroid Biochem 20:391-395, 1984.
40. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr: p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 38:763-770, 1996.
41. Todo T, Buchfelder M, Thierauf P, Fahlbusch R: Immunohistochemical expression of protein kinase C Type III in human pituitary adenomas. Neurosurgery 32:635-642, 1993.
42. Völker W, Gehring WG, Berning R, Schmidt RC, Schneider J, von zur Mühlen A: Impaired pituitary response to bromocriptine suppression: Reversal after bromocriptine plus tamoxifen. Acta Endocrinol 101:491-500, 1982.
43. Wang TTY, Phang JM: Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55:2487-2489, 1995.
44. Wosikowski K, Regis JT, Robey RW, Alvarez M, Buters JT, Gudas JM, Bates SE: Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ 6:1395-1403, 1995.